COMPASS PATHWAYS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.66 USD | -4.03% |
|
-4.03% | -23.89% |
| Jun. 05 | Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating | MT |
| Jun. 04 | FDA panel to review psychedelic drug MDMA for first time | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 455M | - | - | - | - | - | |
| 53.67B | - | |||||
| 38.86B | ||||||
| 38.76B | ||||||
| 27.27B | ||||||
| 25.91B |
